For personal use only

Neuren (NEU) – ASX Announcement **28 February 2024**

DAYBUE™ net sales US$87.1 million in Q4 2023


Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today reported highlights from the Q4 2023 earnings announcement and conference call of its partner Acadia Pharmaceuticals (Nasdaq: ACAD). Acadia announced Q4 net sales of DAYBUE™ (trofinetide) in the United States of US$87.1 million. This was the second full quarter of sales since launch in April 2024. Net sales for 2023 since April were US$177.2 million.


Acadia also provided guidance for full-year net sales in 2024 of between US$370 million and US$420 million.

Anticipated royalties to Neuren are:

- A$12.8 million for Q4 2023 (up from A$10.4 million for Q3 2023)
- A$26.8 million for the full year 2023
- Between A$61 million and A$70 million for the full year 2024 (assuming Acadia guidance is met and exchange rate of 0.65)

The Q4 earnings conference call and presentation can be accessed in the Investors section of the Acadia website www.acadia.com.





* Since launch to 30 Jun 2023
^ Based on 10% of DAYBUE net sales and AUDUSD of 0.6805 for Q4 2023
# Based on 10% of DAYBUE net sales up to US$250m and 12% of DAYBUE net sales between US$250m and US$500m, and AUDUSD of 0.65

About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in Phase 2 development for each of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

Contact:

Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

For personal use only